Center will supply Malarex/MMH 18 order to the Angolan government and the rest of the Africa upon approval.
Millenia Hope signed a memorandum of understanding with Suninvest of Angola, Africa, to establish a production facility in Angola for an antimalaria drug. This plant will supply an envisioned 500,000-treatment Malarex/MMH 18 order from the Angolan government once it has been homologated. The agreement extends the supply to the rest of the African region as well.
“We are very pleased to have concluded this crucial MOU with Suninvest,” says Leonard Stella, chairman, and CEO of Millenia Hope. “Once the infrastructure is in place, we will have a true African presence in our ongoing battle against the devastation of malaria in the African continent.”
Millenia Hope, a Montreal-based U.S. Biopharma, states that it has dedicated its resources for the past nine years to developing its antimalarial drug, Malarex/MMH 18.
